Atea Pharmaceuticals, Inc.
$3.96+$0.03 (+0.8%)
Last close · Data as of Nov 20, 2026
- Market cap
- $353.7M
- P/E
- -2.2x
- EV / EBITDA
- -1.4x
- Revenue
- $0.00
- ROCE
- -65.7%
Price chart
Technical chartScreen technicals →+32.0% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -11.3%
- 3M
- -26.1%
- 6M
- -5.5%
- 1Y
- +32.0%
- 5Y
- -51.2%
52-week range
Day change +$0.03 (+0.8%) from $3.93 to $3.96 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in AVIR, bought on each weekday since 2021.
News & filings
What Atea Pharmaceuticals filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 158 million US dollars in fiscal 2025.
Strengths (1)
- Current assets are 7.82 times current liabilities.
- Revenue is too small for margins and growth rates to be read, so those points are not shown.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Read moreShow less
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Shares outstanding
- 78.1M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $353.7M
- P/E
- -2.2x
- P/B
- 1.3x
- EV / EBITDA
- -1.4x
- 52-week high
- $6.15
- 52-week low
- $2.97
Profitability
- ROE
- -57.5%
- ROCE
- -65.7%
- ROIC
- -79.1%
- ROA
- -50.2%
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $0.00
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -6.0%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- -$132.0M
Solvency
- Current ratio
- 7.82
- Debt / Equity
- 0.00
- Debt / Assets
- 0.00
- CFO / Net profit
- 0.83
- Cash / Market cap
- 27.1%
Revenue and net profit
Annual revenue, with net profit as the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $0.00 | -$115.9M |
| FY2023 | $0.00 | -$136.0M |
| FY2024 | $0.00 | -$168.4M |
| FY2025 | $0.00 | -$158.3M |
Cash flows
FY2025: -$132.0M from operations, -$132.0M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$121.0M | -$122.9M |
| FY2023 | -$85.4M | -$85.4M |
| FY2024 | -$135.5M | -$135.5M |
| FY2025 | -$132.0M | -$132.0M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $0.00
- EBITDA
- -$180.5M
- Net profit
- -$158.3M
- Cash from operations
- -$132.0M
- Free cash flow
- -$132.0M
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $0.00 | -$180.5M | -$158.3M | -$132.0M | -57.5% | — | -6.0% |
Monthly returns
Month-by-month returns of AVIR across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $315.2M |
| Current assets | $311.0M |
| Non-current assets | $4.2M |
| Liabilities | $39.8M |
| Current liabilities | $39.8M |
| Non-current liabilities | $0.00 |
| Equity | $275.4M |
| Paid-in capital | $797.8M |
| Retained earnings | -$522.6M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; AVIR highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Not shown (no positive earnings and no EV / Sales): Atea Pharmaceuticals, Inc., Perspective Therapeutics, Inc., Greenwich LifeSciences, Inc., Larimar Therapeutics, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Atea Pharmaceuticals, Inc.AVIRthis company | $353.7M | -2.2x | 1.3x | -57.5% | -1.4x |
| Perspective Therapeutics, Inc.CATX | $370.7M | -3.6x | 1.8x | -49.8% | -3.4x |
| Puma Biotechnology, Inc.PBYI | $356.8M | 11.5x | 2.7x | 23.9% | 6.7x |
| REGENXBIO Inc.RGNX | $355.7M | -1.8x | 3.5x | -188.7% | -3.0x |
| Greenwich LifeSciences, Inc.GLSI | $347.1M | -22.0x | 137.0x | -623.1% | — |
| Larimar Therapeutics, Inc.LRMR | $341.8M | — | 4.4x | -212.2% | — |
| Enanta Pharmaceuticals, Inc.ENTA | $341.1M | -4.2x | 5.3x | -126.5% | -5.1x |
| Verastem, Inc.VSTM | $339.2M | -1.6x | 5.9x | -366.2% | -1.1x |
| Simulations Plus, Inc.SLP | $336.4M | -5.2x | 2.7x | -51.9% | 20.8x |
| Peer median | — | -3.6x | 3.9x | -157.6% | -2.0x |
Year-to-date ROI
AVIR since 1 January, against earlier years.
Historical volatility
AVIR's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $0.00 |
| Operating expensesOperating Expense | $180.9M |
| Research and developmentResearch And Development | $148.0M |
| Selling, general and administrativeSelling General And Administration | $32.9M |
| Total expensesTotal Expenses | $180.9M |
| Operating incomeOperating Income | -$180.9M |
| Interest and other | |
| Pretax incomePretax Income | -$164.5M |
| TaxTax Provision | -$6.2M |
| Net incomeNet Income | -$158.3M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $315.2M |
| Current assetsCurrent Assets | $311.0M |
| Non-current assetsTotal Non Current Assets | $4.2M |
| LiabilitiesTotal Liabilities Net Minority Interest | $39.8M |
| Current liabilitiesCurrent Liabilities | $39.8M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $0.00 |
| EquityTotal Equity Gross Minority Interest | $275.4M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | -$132.0M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | -$132.0M |
| Net income, continuing operationsNet Income From Continuing Operations | -$158.3M |
| Depreciation and amortisationDepreciation And Amortization | $420.0k |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $420.0k |
| Amortization of securitiesAmortization Of Securities | -$4.9M |
| Stock-based compensationStock Based Compensation | $20.7M |
| Deferred taxDeferred Tax | -$6.4M |
| Deferred income taxDeferred Income Tax | -$6.4M |
| Change in working capitalChange In Working Capital | $16.5M |
| Investing cash flowInvesting Cash Flow | $188.8M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | $188.8M |
| Capital expenditureCapital Expenditure | — |
| Purchase of PP&EPurchase Of PPE | — |
| Net PP&E purchases and salesNet PPE Purchase And Sale | — |
| Purchase of investmentsPurchase Of Investment | -$281.9M |
| Sale of investmentsSale Of Investment | $470.7M |
| Net investment purchases and salesNet Investment Purchase And Sale | $188.8M |
| Financing cash flowFinancing Cash Flow | -$25.7M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$25.7M |
| Shares issuedIssuance Of Capital Stock | $60.0k |
| Common stock issuedCommon Stock Issuance | $60.0k |
| Net common stock issuedNet Common Stock Issuance | -$25.5M |
| Common stock repurchasedCommon Stock Payments | -$25.5M |
| Share buybacksRepurchase Of Capital Stock | -$25.5M |
| Stock options exercisedProceeds From Stock Option Exercised | $200.0k |
| Preferred stock issuancePreferred Stock Issuance | — |
| Net preferred stock issuanceNet Preferred Stock Issuance | — |
| Other financing chargesNet Other Financing Charges | -$480.0k |
| Change in cashChanges In Cash | $31.0M |
| Cash at the start of the yearBeginning Cash Position | $64.7M |
| Cash at the end of the yearEnd Cash Position | $95.7M |
| Free cash flowFree Cash Flow | -$132.0M |
Learn while you research
Academy chapters picked for Atea Pharmaceuticals, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read